Zhittya Genesis Medicine

What Zhittya Genesis Medicine does

Zhittya Genesis Medicine is a Nevada-based, privately-held clinical-stage biotechnology company founded in 1998 by Daniel Montano, Dr. Jack Jacobs, and Viktoriya Tamlenova-Montano to commercialize Fibroblast Growth Factor 1 (FGF-1), a naturally occurring human protein responsible for angiogenesis (new blood vessel growth) and neurogenesis (new neuron growth). The company's central hypothesis is that insufficient natural FGF-1 production underlies slow-developing ischemic diseases, and that exogenous FGF-1 can restore perfusion to affected tissues. Over 20+ years and approximately $150M of cumulative R&D expenditure (self-funded by the founding Montano family), Zhittya has advanced FGF-1 through FDA-authorized clinical trials across multiple indications, including coronary artery disease (Phase IIA, with results published in Circulation), diabetic foot ulcers (Phase II, with 100% complete closure in treated patients and no adverse events), and Parkinson's Disease (medical research studies dosing 200+ patients with reported 53% average motor score improvement). The company has also expanded into Type 2 Diabetes (100-participant intranasal study announced December 2025), Alzheimer's/vascular dementia, stroke recovery, Long COVID, and autism spectrum disorder, targeting 19 of 75+ vascular-related human diseases.

The product portfolio is a single platform therapeutic (FGF-1) deployed across multiple indication programs, administered via injection for angiogenic indications and intranasally for metabolic/neurological applications. Zhittya has not yet commercialized any product and generates no product revenue; current operations consist of medical research studies dosing patients directly in the United States. The planned go-to-market model relies on a marketing and distribution partnership with WUND Healing BioPharmaceuticals (Las Vegas) for post-approval commercialization, supported by patient logistics from Cross Border Medical Tourism (Los Angeles). Academic and clinical partners include the University of Cincinnati (Phase I CAD trial), Fulda Medical Center in Germany (first-in-human CAD study), and the Nevada Biotechnology Consortium. Leadership is family-controlled, with multiple Montano family members in CEO, VP Drug Development, VP Marketing, and VP roles, and the company has not disclosed institutional venture capital, private equity, or public market funding to date.

Name

Zhittya Genesis Medicine

Legal name

Zhittya Genesis Medicine Inc.

Website

https://zgm.care

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Zhittya Genesis Medicine is a privately-held, Las Vegas-based clinical-stage biotechnology company developing FGF-1 protein therapy for vascular, neurodegenerative, and metabolic diseases including Parkinson's, Alzheimer's, coronary artery disease, diabetic foot ulcers, and Type 2 diabetes.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Angiogenesis therapy
• Biopharmaceutical drug development
• Regenerative medicine research
• Vascular disease treatment
• Growth factor therapeutics

Headquarters

HQ city

Las Vegas

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Once FDA approval is obtained, the company plans to commercialize FGF-1 as a biological drug for treating multiple diseases characterized by lack of blood flow. Revenue will come from selling the approved therapeutic product directly to healthcare providers and patients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Zhittya Genesis Medicine develops and clinically tests recombinant human FGF-1 (Fibroblast Growth Factor 1) therapies that trigger the body to grow new blood vessels and neural connections, addressing the root biological cause of diseases marked by insufficient blood flow. The company is advancing multiple indication-specific programs (Parkinson's disease, coronary artery disease, diabetic foot ulcers, type 2 diabetes, Alzheimer's/vascular dementia, autism, stroke recovery, and long COVID) via injectable and intranasal administration under FDA-approved investigational protocols. It is currently treating patients in clinical research studies rather than selling an approved product.

Product overview

Zhittya Genesis Medicine is a biotechnology company commercializing FGF-1 (Fibroblast Growth Factor 1), a naturally-occurring protein that stimulates angiogenesis (new blood vessel growth) and neurogenesis. The company offers a single core therapeutic product—the FGF-1 therapy—which is being developed across multiple indication programs including Parkinson's Disease, Coronary Artery Disease, Chronic Wounds (Diabetic Foot Ulcers), Type 2 Diabetes, Autism Spectrum Disorder, Diseases of Memory (Alzheimer's/Vascular Dementia), Stroke Recovery, and Long COVID. The therapy is administered via injection or intranasal delivery and works by promoting new blood vessel formation in ischemic tissues to restore blood flow.

Differentiator

Problem solved

Functional benefit

Products and services

• FGF-1 Therapy Platform Recombinant human Fibroblast Growth Factor 1 (FGF-1) therapy that induces angiogenesis and neurogenesis to treat diseases caused by insufficient blood flow, delivered via injection or intranasal administration. Being developed for multiple indications and currently dosed in FDA-approved clinical research studies.
• FGF-1 Therapy for Parkinson's Disease Investigational FGF-1 therapy administered as injections to grow new blood vessels and neurons in the brain of Parkinson's Disease patients, conducted under an FDA-approved Phase I clinical trial and dosed either in office or at home. Reported results include a 53% improvement in motor function scores after a single treatment and an average of four months of motor improvement per dose.
• FGF-1 Therapy for Coronary Artery Disease Investigational FGF-1 therapy injected directly into the heart muscle by an interventional cardiologist under echocardiographic guidance to grow new coronary blood vessels in patients with advanced coronary artery disease who have no further catheter-based or surgical options.
• FGF-1 Therapy for Chronic Wounds (Diabetic Foot Ulcers) Investigational FGF-1 therapy applied directly to chronic non-healing diabetic foot ulcers with weekly dressing changes, with completed Phase II data showing 100% closure of treated ulcers at 25 weeks. The program is approved by the FDA and Mexico's COFEPRIS and is advancing toward a 250-patient Phase III trial.
• FGF-1 Therapy for Type 2 Diabetes Investigational FGF-1 therapy delivered intranasally to lower blood sugar and trigger insulin expression in Type 2 Diabetes patients, based on a January 2022 Salk Institute discovery. Human study results were released December 4, 2025.
• FGF-1 Therapy for Autism Spectrum Disorder Investigational FGF-1 therapy for Autism Spectrum Disorder designed to cross the blood-brain barrier, normalize capillary density, and improve behavioral metrics in children with autism.
• FGF-1 Therapy for Alzheimer's Disease / Vascular Dementia Investigational FGF-1 therapy aimed at reversing memory loss in Alzheimer's Disease and vascular dementia by growing new brain capillaries, neurons, and synapses via the molecule's ability to cross the blood-brain barrier.
• FGF-1 Therapy for Stroke Recovery Investigational FGF-1 therapy for stroke patients designed to grow new cerebral capillaries, neurons, and neural connections to reverse damage from both acute and chronic stroke.
• FGF-1 Therapy for Long COVID Investigational FGF-1 therapy addressing Long COVID by restoring normal capillary density, reducing inflammation, and reversing post-COVID neurological symptoms linked to SARS-CoV-2 damage to brain microvasculature.

Quantifiable outcome

• 53% average improvement in motor scores for Parkinson's patients
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• WUND Healing BioPharmaceuticalscoreChannel Partner/ Reseller/ DistributorZhittya Genesis Medicine's marketing partner based in Las Vegas, Nevada. WUND Healing BioPharmaceuticals will help market and distribute potential treatments following anticipated approval by the US FDA and other regulatory bodies. This is a key partnership for commercialization strategy.
• Cross Border Medical TourismcoreImplementation/ SI/ Consulting PartnerZhittya Genesis Medicine's partner in patient facilitation, patient logistics, and operations based in Los Angeles, California. Cross Border Medical Tourism helps ensure that all patients are cared for throughout the company's clinical programs.
• Nevada Biotechnology Consortium (NevBio)minorStrategic or Co-development PartnerAs a Nevada biotech company, Zhittya Genesis Medicine supports NevBio's work in ensuring Nevada stays competitive in the biotechnology space. Zhittya has worked hand-in-hand with NevBio on various events and platforms to allow other biotechnology companies to develop in Nevada.
• University of CincinnaticoreStrategic or Co-development PartnerPartnership for US FDA Phase I Clinical Trial for coronary artery disease treatment. 21 patients were recruited for this trial resulting in statistical improvements after only 12 weeks.
• Fulda Medical Center (Germany)coreStrategic or Co-development PartnerFirst coronary artery disease trial in humans with FGF-1 was performed at the Fulda Medical Center in Fulda, Germany. 40 patients were in the study with 20 receiving FGF-1. All 20 patients showed observable new blood vessels on angiograms.

Scale indicators8 records

Recent moves2 records

Expansion highlights6 records

Direct peers

• Organogenesis: Organogenesis is a commercial-stage wound healing and regenerative medicine company whose diabetic foot ulcer portfolio directly overlaps with Zhittya's DFU program. They represent a more advanced commercial peer in chronic wound indications.
• Helixmith: Helixmith (formerly ViroMed) develops angiogenic gene therapies for cardiovascular and neurological indications, including Engensis for diabetic peripheral neuropathy. They pursue similar therapeutic angiogenesis strategy across multiple vascular-related indications.
• FibroGen: FibroGen directly works on FGF biology and related pathways (HIF, CTGF) and is the closest comparable in the FGF therapeutic space. Both companies develop biologics targeting fibroblast growth factor-related mechanisms across multiple indications.
• AnGes MG: AnGes develops gene therapy and biologics for cardiovascular disease, including angiogenic approaches (HGF plasmid for peripheral artery disease). They are a comparable therapeutic angiogenesis peer with similar cardiovascular and ischemic disease focus.

Emerging players

• Neovasc: Neovasc develops products for refractory angina and other coronary artery disease indications. They are a comparable peer in treating no-option CAD patients, the same population Zhittya's FGF-1 CAD program targets.
• Capstone Therapeutics: Capstone Therapeutics has worked on regenerative biologics and growth-factor-based therapies. They represent an earlier-stage peer exploring similar protein therapeutics for tissue repair and vascular indications.
• Cerevel Therapeutics: Cerevel develops neuroscience therapeutics including Parkinson's Disease treatments. While their mechanism differs from FGF-1, they target the same Parkinson's indication and represent a relevant competitive peer for that program.
• Cardium Therapeutics: Cardium Therapeutics has historically developed cardiovascular biologics including angiogenic approaches. They are a comparable, smaller-cap peer pursuing cardiovascular regeneration therapies.

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron is a large biologics company with protein therapeutics expertise (VEGF Trap, antibody platforms). While they don't target FGF-1 specifically, their protein-based regenerative biology work is comparable in scale and technology class.
• Amgen: Amgen is a major biologics manufacturer with cardiovascular and metabolic franchises (e.g., Repatha). They represent a broad incumbent with comparable therapeutic categories across Zhittya's cardiometabolic and vascular indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Zhittya_MENA
• Facebookfacebook.com/zgminc
• LinkedInlinkedin.com/company/zhittya-genesis-medicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zhittya Genesis Medicine